Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing…
| Periodo | 2026-08 |
|---|---|
| Real | — |
| Estimado | — |
| Sorpresa | — |
| Métrica | ONT.L | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 58.6% | 57.4% | +1.3% |
| Operating Margin | -69.4% | -34.4% | -35.0% |
| Net Margin | -64.8% | -32.5% | -32.4% |
| FCF Margin | -33.1% | -12.6% | -20.5% |
| ROE | -31.3% | -39.2% | +7.8% |
| ROA | -23.3% | -30.9% | +7.6% |
| Current Ratio | 3.56 | 2.73 | +0.83 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -23.3% | — |
| ✗Flujo de caja operativo positivo | −£71M | −£110M |
| ✗Rentabilidad sobre activos al alza | -23.3% | -19.7% |
| ✓Caja operativa/activos supera al ROA | -11.3% | ROA -23.3% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 3.56 | 4.66 |
| ✗Sin aumentar el nº de acciones | — | — |
| ✓Margen bruto al alza | 58.6% | 57.5% |
| ✓Rotación de activos al alza | 0.36 | 0.25 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -33.1% |
| ✗ROCE > 10 % | -30.8% |
| ✗Ventas > 5 %/año (3 años) | 4.1% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 45.2% |
Riesgo de quiebra (Altman Z 6.3): zona segura
OXFORD NANOPORE TECHNOLOGIES PLC cotiza a 2.00 GBP y tiene una capitalización bursátil de £2.0B. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud